Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. This growth was largely driven by approximately $11 million in net sales of TONMYA, the company's recently approved fibromyalgia treatment. The drug recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%.
The strong performance underscores the market's acceptance of TONMYA, which is the first new treatment for fibromyalgia in over 15 years. Tonix has achieved coverage for TONMYA representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on January 1, 2027, further broadening patient access.
Beyond its commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These initiatives demonstrate Tonix's commitment to addressing high unmet medical needs in central nervous system and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its current resources, combined with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial stability provides a solid foundation for ongoing product commercialization and pipeline development.
The robust revenue growth and expanded coverage for TONMYA are critical for Tonix's long-term viability. With a strong commercial infrastructure supporting TONMYA and other products like Zembrace SymTouch and Tosymra for acute migraine, Tonix is well-positioned to capitalize on its CNS franchise. The company's focus on maximizing the science behind TONMYA through Phase 2 trials in major depressive disorder and acute stress disorder could open new indications and further revenue streams.
As Tonix moves forward, the successful launch of TONMYA and the progress of its pipeline are key indicators of its potential to deliver value to patients and shareholders alike. The company's ability to secure broad payer coverage and generate increasing prescription volumes reflects a strategic execution that bodes well for its future performance.
